Occidental Petroleum stock holds steady as Jefferies maintains $44 target

Occidental Petroleum is divesting its OxyChem unit for approximately $9.75 billion, a strategic move Jefferies views as addressing debt and preferred share overhangs despite being "marginally dilutive" to cash flow per share. This divestiture, which is reportedly attracting interest from Berkshire Hathaway, has elicited mixed analyst reactions, with HSBC upgrading OXY on valuation while Evercore ISI lowered its price target due to concerns over the business impact, highlighting divergent views on the long-term implications of OXY's balance sheet de-risking.

Analysis

Occidental Petroleum (OXY) is executing a significant balance sheet restructuring through the divestiture of its OxyChem unit for $9.75 billion, a valuation representing approximately 5.5 times normalized 2027 EBITDA. According to Jefferies, this transaction, while being "marginally dilutive" by causing an estimated 5% dilution to cash flow per share, strategically addresses critical investor concerns regarding debt overhang. The deal's financial trade-off involves a $1.2 billion loss in EBIT, partially mitigated by $350 million in annual interest savings. The proceeds are earmarked to help retire approximately $8.5 billion in preferred shares by 2029. Analyst sentiment is sharply divided on the move's net effect, highlighting market uncertainty. HSBC upgraded OXY to 'Buy' with a $55 price target, viewing the stock's recent decline as a valuation opportunity, whereas Evercore ISI reiterated an 'Underperform' rating and cut its target to $38, citing concerns over the removal of the chemicals business. UBS remains neutral with a $46 target, while reports of potential interest from Berkshire Hathaway add a notable dimension to the transaction.

Key Decisions for Investors

• Investors should weigh the immediate 5% cash flow per share dilution against the long-term strategic benefit of de-risking the balance sheet and retiring the high-cost preferred shares.
• The wide dispersion in analyst price targets, from Evercore's $38 to HSBC's $55, signals significant market uncertainty and suggests potential for near-term volatility as investors digest the implications of the divestiture.
• Monitor for confirmation and final terms of the OxyChem sale, as well as management's subsequent execution on its stated capital allocation plan to retire the preferred stock by 2029.